<?xml version="1.0"?>
<template xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="openEHR/v1/Template">
  <id>d4487aeb-47cb-4f00-b0b7-d61fca711a62</id>
  <name>Antineoplastic Agent aGVHD second line treatment oncology adult Order Group</name>
  <description>
    <lifecycle_state>Initial</lifecycle_state>
    <details>
      <purpose/>
      <use/>
      <misuse/>
    </details>
    <other_details>
      <item>
        <key>MetaDataSet:Sample Set </key>
        <value>Template metadata sample set </value>
      </item>
      <item>
        <key>Acknowledgements</key>
        <value/>
      </item>
      <item>
        <key>Business Process Level</key>
        <value/>
      </item>
      <item>
        <key>Care setting</key>
        <value/>
      </item>
      <item>
        <key>Client group</key>
        <value/>
      </item>
      <item>
        <key>Clinical Record Element</key>
        <value/>
      </item>
      <item>
        <key>Copyright</key>
        <value/>
      </item>
      <item>
        <key>Issues</key>
        <value/>
      </item>
      <item>
        <key>Owner</key>
        <value/>
      </item>
      <item>
        <key>Sign off</key>
        <value/>
      </item>
      <item>
        <key>Speciality</key>
        <value/>
      </item>
      <item>
        <key>User roles</key>
        <value/>
      </item>
    </other_details>
  </description>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]">
    <items>
      <item>
        <key>Technical.ï»© Technical Traceability</key>
        <value>{~AHSID~d4487aeb-47cb-4f00-b0b7-d61fca711a62~NAME~Antineoplastic Agent aGVHD second line treatment oncology adult Order Group}</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.clinical_guidance.v1]">
    <items>
      <item>
        <key>CKT.Clinical Guidance</key>
        <value>&lt;p&gt;Patients who have a response to ruxolitinib may be tapered gradually after eight weeks. Gradual taper is important because a &quot;withdrawal syndrome&quot; that resembles systemic inflammatory response syndrome may be seen when ruxolitinib is discontinued in myelofibrosis.&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-INSTRUCTION.service_request.v1]/activities[at0001]">
    <items>
      <item>
        <key>Transform.Clinical Notes</key>
        <value>&lt;p&gt;Default dose 5 mg&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <definition xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" name="Antineoplastic Agent">
    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" path="/items"/>
    <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="1b4965e4-58a0-4491-b876-372a730dff4b" concept_name="PHARM ruxolitinib Tablet Order" max="1" path="/items" name="ruxolitinib Tablet; 5 mg, oral, 2 times per day, as scheduled"/>
    <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items"/>
  </definition>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.adhoc.v1">
    <digest id="MD5-CAM-1.0.1">8AE70853975A75254E6D39A8DE3652AF</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1">
    <digest id="MD5-CAM-1.0.1">4B2F0F6CD593E442DA9C30277A3EA9CF</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1">
    <digest id="MD5-CAM-1.0.1">AD8DFB192E67715F0D9E11E95E674AD0</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.service_request_information.v1">
    <digest id="MD5-CAM-1.0.1">230A8D964017E1FD7AC82EBDEE0202A6</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1">
    <digest id="MD5-CAM-1.0.1">A7EC4E4C870D8C3431B29F6514353416</digest>
  </integrity_checks>
</template>